Be Biopharma raised $92m in Series C funding to progress its haemophilia B and hypophosphatasia clinical programs. The investment will support clinical trials for BE-101 and BE-102, aiming to demonstrate proof-of-concept and provide innovative treatment options.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing